Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676463 · ClinicalTrials.gov registry record · Phase 2
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
A Phase 2 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05676463: Clinical Trial Phase 2 study, sponsored by Thomas Jefferson University.
NCT05676463 is a Phase 2 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05676463, a Phase 2 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.
Primary Outcome
Per Common Terminology Criteria for Adverse Events version 5.0 compared to rate of toxicity in POP-RT trial. Will be estimated for the entire sample that receives the intervention, treating death from any cause (other than treatment) as a competing risk and censoring subjects who drop out before experiencing toxicity at time of last follow-up. A point estimate of cumulative incidence at 1 year will be estimated from this curve along with a two-sided 90% confidence interval. If the upper bound of
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Antiandrogen Therapy
- PROCEDURE PSMA PET Scan
- PROCEDURE MRI-guided Intensity-Modulated Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2025-10-24 |
| Phase | Phase 2 |
Why NCT05676463 stopped before completion
NCT05676463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05676463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05676463 about?
NCT05676463 is a clinical study titled "MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer". This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a sho...
What is the current status of trial NCT05676463?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-11-16. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT05676463?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Antiandrogen Therapy (DRUG), PSMA PET Scan (PROCEDURE), MRI-guided Intensity-Modulated Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05676463?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05676463's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI